According to latest reports, Aarti Drugs delivered stronger Q4 FY26 performance with consolidated net profit rising 16% year-on-year to ₹55 crore compared with ₹47.4 crore in the corresponding period last year. The company also demonstrated robust sequential growth with profit increasing 36% quarter-on-quarter from ₹40.5 crore in Q3 FY26. Revenue from operations surged 20% year-on-year to ₹720.3 crore from ₹601.7 crore in the same quarter last year, while showing 6.9% sequential growth from ₹673 crore in Q3 FY26. The company's total income stood at ₹721.1 crore during the March quarter, higher than ₹673.6 crore in Q3 FY26 and ₹602.9 crore in Q4 FY25. Earnings per share increased to ₹6.05 in Q4 FY26 compared to ₹4.44 in Q3 FY26 and ₹5.88 in the same quarter last year, reflecting improved profitability across all metrics.
The company's Q4 performance showed strong sequential momentum with profit rising 36% quarter-on-quarter from ₹40.5 crore in Q3 FY26, demonstrating consistent growth across quarters. Revenue grew 6.9% sequentially from ₹673 crore in Q3 FY26, indicating sustained business activity and operational efficiency. This sequential improvement contrasts with the year-on-year performance trends, where the company faced operational and financial pressures that impacted the bottom line despite steady revenue growth. The profit before tax increased to ₹70.4 crore from ₹53.7 crore in the year-ago quarter and ₹63 crore in the previous quarter, showing improved operational leverage and cost management.
According to the latest financial statements, the company's EBITDA performance showed some pressure with total expenses rising to ₹650.7 crore from ₹610.6 crore in Q3 FY26 and ₹549.2 crore in Q4 FY25. Employee benefit expenses stood at ₹31.2 crore, while finance costs were ₹9.3 crore during the quarter, contributing significantly to the cost structure. The company's EBITDA margin held steady at 13.3% compared to 13.8% in the prior year, indicating that while core business operations performed adequately, higher costs further down the income statement ate into these gains. The expenses increased due to higher raw material and operating costs, reflecting the company's investment in business growth and operational expansion during the quarter.
As per recent reports, Aarti Drugs maintained its strategic focus on the pharmaceutical sector during Q4 FY26, with the company expanding through subsidiaries and prudent capital allocation to strengthen its market position. The company's audited financial results for the quarter and year ended March 31, 2026 received unmodified opinions from auditors Gokhale & Sathe, providing confidence in the accuracy of the financial statements. The company's return on equity (ROE) has averaged around 13.5% over the last three years, which industry watchers consider relatively low compared to the industry's average profit growth, though the company continues to focus on operational efficiency and strategic expansion.
